Johnson Pharma

Why is Johnson Pharmacare Ltd falling/rising?

As of 01-Sep, Johnson Pharmacare Ltd's stock price is rising to Rs 0.47, up 2.17%, but it has decreased by 18.97% year-to-date and 39.74% over the past year, indicating a troubling long-term trend despite today's gains. Additionally, investor participation is declining, with delivery volume down 2.09% from the 5-day average.

As of 01-Sep, Johnson Pharmacare Ltd's stock price is rising, currently at Rs 0.47, reflecting an increase of Rs 0.01 or 2.17%. This upward movement is notable as it has outperformed its sector by 2.99% today. Additionally, the stock is currently trading higher than its 5-day moving averages, which may indicate a short-term positive trend. <BR><BR>However, it is important to consider the broader context of the stock's performance. Year-to-date, the stock has decreased by 18.97%, and over the past year, it has fallen by 39.74%. Despite today's rise, the stock is still close to its 52-week low, being only 4.26% away from Rs 0.45. Furthermore, there has been a decline in investor participation, with delivery volume falling by 2.09% compared to the 5-day average. <BR><BR>In summary, while Johnson Pharmacare Ltd is experiencing a rise in stock price today, this is set against a backdrop of significant declines over the longer term and decreasing investor engagement.

Who are in the management team of Johnson Pharma?

The management team of Johnson Pharma includes Ramanlal Trivedi (Whole Time Director & CFO), Pareshbhai Sengal (Independent Director), and Manisha Maneklal Patel (Independent Director).

The management team of Johnson Pharma includes the following individuals:<BR><BR>1. Ramanlal Trivedi - Whole Time Director & CFO<BR>2. Pareshbhai Sengal - Independent Director<BR>3. Manisha Maneklal Patel - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Johnson Pharma do?

Johnson Pharmacare Ltd is a micro-cap pharmaceutical company, originally incorporated in 1994, that reported a net profit of -1 Cr for June 2026 and has a market cap of INR 26 Cr. The company has a high debt-equity ratio of 21.32 and a return on equity of -4,146.00%.

Overview:<BR>Johnson Pharmacare Ltd is a pharmaceutical company operating in the diversified commercial services industry and classified as a micro-cap.<BR><BR>History:<BR>The company was originally incorporated in 1994 as 'Robinson Worldwide Trade Limited'. It underwent name changes to 'Sun & Shine Worldwide Limited' in September 2011 and to 'Johnson Pharmacare Limited' on August 23, 2021. The latest quarterly results reported are for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 26 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 21<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 21.32<BR>Return on Equity: -4,146.00%<BR>Price-to-Book: 25.85<BR><BR>Contact Details:<BR>Address: Office No 302 Munisuvrat Navg, NTC B-68 Swastik Society CG Rd Ahmedabad Gujarat : 380009<BR>Email: sunandshineworldwideltd@gmail.com<BR>Website: http://www.sunandshineworldwidetradelimited.quest

Who are the peers of the Johnson Pharma?

Johnson Pharma's peers include Parle Industries, S P Capital Fin., ERP Soft Systems, and others. In terms of performance, Johnson Pharma has a Below Average growth rating and the lowest 1-year return at -40.26% compared to its peers.

Peers: The peers of Johnson Pharma are Parle Industries, S P Capital Fin., ERP Soft Systems, Innovative Ideal, Shreevatsaa Fin., Disha Resources, Enbee Trade, Monotype India, and Vrundavan Planta.<BR><BR>Quality Snapshot: Excellent management risk is observed at S P Capital Fin. and Disha Resources, while Below Average management risk is found at Parle Industries, ERP Soft Systems, Innovative Ideal, Johnson Pharma, Enbee Trade, Vrundavan Planta, and the rest. Growth is rated as Excellent for Disha Resources and Enbee Trade, Average for Johnson Pharma, and Good for S P Capital Fin., while Below Average growth is noted for Parle Industries, ERP Soft Systems, Innovative Ideal, and the rest. Capital Structure is Excellent at S P Capital Fin. and Disha Resources, Good at Parle Industries, Johnson Pharma, and Vrundavan Planta, and Below Average at Innovative Ideal, ERP Soft Systems, Enbee Trade, and the rest.<BR><BR>Return Snapshot: Disha Resources has the highest 1-year return at 74.01%, while Johnson Pharma has the lowest at -40.26%. Compared to its peers, Johnson Pharma's return is significantly lower. Additionally, the six-month return is negative for Parle Industries, ERP Soft Systems, Innovative Ideal, Enbee Trade, Monotype India, and Johnson Pharma.

How big is Johnson Pharma?

As of 31st August, Johnson Pharmacare Ltd has a market capitalization of 26.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 56.77 Cr in the latest four quarters. Shareholder's Funds are 56.17 Cr and Total Assets are valued at 57.93 Cr as of March 2025.

As of 31st August, Johnson Pharmacare Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Johnson Pharmacare Ltd reported Net Sales of 0.00 Cr and a Net Profit loss of 56.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 56.17 Cr and Total Assets valued at 57.93 Cr.

Which are the latest news on Johnson Pharma?

Should I buy, sell or hold Johnson Pharmacare Ltd?

Are Johnson Pharmacare Ltd latest results good or bad?

Johnson Pharmacare Ltd's latest results are concerning, showing a net loss of ₹55.61 crores in Q4 FY26 and no revenue for the past seven quarters. With a return on equity of -4,146% and a high price-to-book ratio of 29.15x, the company is in deep financial distress, indicating a negative outlook for investors.

The latest results for Johnson Pharmacare Ltd are quite concerning. In Q4 FY26, the company reported a net loss of ₹55.61 crores, which is a staggering decline of over 10,800% year-over-year. Additionally, the company has not generated any revenue for the past seven consecutive quarters, indicating a complete operational standstill.<BR><BR>The return on equity (ROE) has plummeted to an alarming -4,146%, highlighting severe capital erosion. The stock is currently trading at a price-to-book value ratio of 29.15x, which is extremely high for a company with no operational revenue and significant losses. <BR><BR>Overall, these results reflect a company in deep financial distress with no visible path to recovery, making the outlook quite negative. Investors should approach this stock with caution, as it presents multiple red flags regarding its viability and future prospects.

When is the next results date for Johnson Pharmacare Ltd?

The next results date for Johnson Pharmacare Ltd is 14 February 2026.

The next results date for Johnson Pharmacare Ltd is scheduled for 14 February 2026.

How has been the historical performance of Johnson Pharma?

Johnson Pharma has experienced significant declines in revenue and profitability, with net sales dropping from 3.26 Cr in March 2022 to 0.00 Cr by March 2025, resulting in increasing operating and net losses. Total assets and liabilities decreased, and cash flow turned negative, indicating a downward trend in financial stability.

Answer:<BR>The historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Johnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr to 57.93 Cr in the same period. Cash flow from operating activities turned negative, with a cash outflow of 1.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2022. Overall, the financial data indicates a downward trajectory in both operational performance and financial stability for Johnson Pharma.

Is Johnson Pharma overvalued or undervalued?

As of May 27, 2024, Johnson Pharma is considered overvalued with a PE ratio of -48.95 and has seen a year-to-date decline of 21.05%, indicating a challenging market position compared to its peers.

As of 27 May 2024, Johnson Pharma's valuation grade has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently assessed as overvalued, with a PE ratio of -48.95, an EV to EBIT of -50.90, and an EV to Capital Employed of 0.87. These ratios suggest that the company's earnings and operational efficiency are under considerable strain, leading to negative valuations.<BR><BR>In comparison to its peers, Johnson Pharma's valuation metrics are starkly unfavorable. For instance, MMTC, categorized as risky, has a PE ratio of 119.39, while Optiemus Infra, deemed fair, boasts a PE of 82.35. The stark contrast in these ratios highlights Johnson Pharma's challenging position within the diversified commercial services sector. Furthermore, the company's recent stock performance shows a year-to-date decline of 21.05%, in contrast to the Sensex's 5.58% gain, reinforcing the notion that Johnson Pharma is struggling relative to broader market trends.

What is the technical trend for Johnson Pharma?

As of April 30, 2025, Johnson Pharma's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, RSI, and Bollinger Bands on both weekly and monthly charts, despite a mildly bullish KST on the weekly.

As of 30 April 2025, the technical trend for Johnson Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart and a bearish RSI on the monthly chart. Both Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The daily moving averages confirm a bearish outlook. Although the KST shows mildly bullish on the weekly, it is mildly bearish on the monthly, indicating a lack of strong upward momentum. Overall, the bearish sentiment is reinforced by the Dow Theory, which shows a mildly bearish trend on the weekly and no trend on the monthly.

Who are the top shareholders of the Johnson Pharma?

The top shareholders of Johnson Pharma are primarily individual investors, holding 85.56% of the shares, with Jagkarta Agencies Private Limited as the largest public shareholder at 2.78%. There are no institutional holdings or pledged promoter holdings reported.

The top shareholders of Johnson Pharma primarily consist of individual investors, who hold a significant 85.56% of the shares. The highest public shareholder is Jagkarta Agencies Private Limited, with a holding of 2.78%. There are no institutional holdings or pledged promoter holdings reported, and no mutual funds or foreign institutional investors are involved.

What is the bonus history of the Johnson Pharma?

Johnson Pharma announced a 1:10 bonus issue on April 7, 2022, with a record date of April 8, 2022, meaning shareholders received one additional share for every ten shares held.

Johnson Pharma has a recent bonus history that includes a 1:10 bonus issue announced on April 7, 2022. The record date for this bonus was April 8, 2022. This means that for every 10 shares held, shareholders received an additional share as part of the bonus issue. If you have any more questions about the company or its financials, feel free to ask!

Has Johnson Pharma declared dividend?

No Dividend History Available